High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma

New England Journal of Medicine

Volumn 336, Issue 18, 1997, Pages 1290-1297

  Gianni, Alessandro M ^a,b,d   Bregni, Marco ^a,b   Siena, Salvatore ^a,b   Brambilla, Cristina ^a,b   Di Nicola, Massimo ^a,b   Lombardi, Fabrizio ^a,b   Gandola, Lorenza ^a,b   Tarella, Corrado ^c   Pileri, Alessandro ^c   Ravagnani, Fernando ^a,b   Valagussa, Pinuccia ^a,b   Bonadonna, Gianni ^a,b   Stern, Angelika C ^e   Magni, Michele ^f   Caracciolo, Daniele ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Ist Naz Per lo Stud E la Cura D ^*  (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Sandoz Clinical Research   (Switzerland)

^f Istituto per la Ricerca e la Cura Dei Tumori   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DERMATITIS; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE DEFICIENCY; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PREDNISOLONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0030973746     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199705013361804     Document Type: Article

References (25)

1. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-8.
2. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-81.
3. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancer 1988;1: 1194-8.
4. Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemotopoietic stem cells for autotransplantation. Lancet l989;2:580-5.
5. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985;102.596-602.
6. Gianni AM, Bonadonna G. High dose chemo-radiotherapy for sensitive tumors: is sequential better than concurrent drug delivery? Eur J Cancer Clin Oncol 1989;25:1027-30.
7. Gianni AM, Siena S, Bregni M, et al. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease - a 6-year update. Ann Oncol 1993;4:889-91.
8. Gianni AM, Tarella C, Bregni M, et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol 1994;12:503-9.
9. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
10. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986;104:757-65.
11. Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 199l;9:211-9.
12. The International Non-Hodgkin s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphomas. N Engl J Med l993;329:987-94.
13. Gianni AM, Bregni M, Siena S, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990;8:768-78.
14. Gianni AM, Bregni M, Siena S, et al. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J Clin Oncol 1992;10:1955-62.
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am I Clin Oncol 1982; 5:649-55.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Peto R, Peto J. Asymptotically efficient rank invariant test procedures, J R Stat Soc [A] 1972;135:185-206.
18. Shipp MA, Klatt MM, Yeap B, et al. Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. J Clin Oncol 1989;7:613-8.
19. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
20. Verdonck LF, van Putten WLJ, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995;332:1045-51.
21. Haioun C, Lepage E, Gisselbrecht C, et al. Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive non Hodgkin's lymphoma (NHL) in first complete remission. Blood 1995;86: Suppl 1:457a. abstract.
22. Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. I Clin Oncol 1996;14:534-42.
23. Gisselbrecht C, Lepage E, Morel P, et al. Short and intensified treatment with autologous stem cell transplantation (ASCT) versus ACBV regimen in poor prognosis aggressive lymphoma: prognostic factors of induction failure. Ann Oncol 1996;7:Suppl 3:18. abstract.
24. Vitolo U, Cortellazzo S, Liberati AM, et al. Intensified and high dose chemotherapy with granulocyte colony-stimulating factor and autologous stem cell transplantation support as first line therapy in high risk large cell lymphoma. J Clin Oncol 1997;15:491-8.
25. Gianni AM, Bonadonna G. Important topics for future clinical trials in non-Hodgkin's lymphomas. In: Magrath I, ed. The non-Hodgkin's lymphomas. London: Edward Arnold, 1997:1055-63.